KRAS mutations are among the most commonly found in NSCLC (around 30% of all cases) [31], with the G12C alteration being the most frequent (40% of all KRAS mutations); they are often associated with high PD-L1 expression and higher tumor mutational burden and are mostly considered a poor prognostic biomarker [35,36]. This evidence concerns the gene KRAS and neoplasm.